A L62.0 million ($117.3 million) study of 500,000 people across the UK has been given the go-ahead by the UK Biobank's financial backers, after a positive report endorsed a pilot study in the Greater Manchester area. The UK government and the Wellcome Trust, a UK-based health care research charity, consider the "visionary" project to offer a unique opportunity to study the relationship between genes, lifestyle and the environment, in terms of measuring individuals' risks of developing specific diseases.
UK Biobank was criticized for "over-ambition"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze